Panacea Biotec
PANACEABIONSE

Panacea Biotec

₹411.10-2.55 (0.62%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
403.55
Today’s high
420.40
52 week low
292.40
52 week high
647.00
Open price
413.65
Previous close
413.65
Live volume
1,26,999
Lower circuit
372.30
Upper circuit
455.00

Fundamentals

Market Cap
₹2,536Cr
ROE
-2.93%
P/E Ratio(TTM)
--
EPS(TTM)
-1.46
P/B Ratio
3.04
Dividend Yield
0.00%
Industry P/E
37.23
Book Value
136.30
Debt to Equity
0.03
Face Value
1

Financial performance

Quarterly
Yearly
All Financials
JUN '26
Revenue (Cr)
₹204
+20.38%
Profit (Cr)
₹2.20
+320.00%
-75075150225
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Revenue growthValue
1Y (TTM)+18%
3Y CAGR-5%
Profit growthValue
1Y (TTM)-44%

About

Panacea Biotec is a premier biotechnology company with over three decades of experience in the development, manufacturing, and commercialization of vaccines and pharmaceutical formulations. Its vision is to become a 'Leading Health Management Company' by creating solutions that meet a wide variety of healthcare needs. Guided by its mission of 'Innovation in Support of Life,' the company focuses on delivering scientific advancements that are both accessible and affordable. The company specializes in innovative vaccines and high-quality generic medicines, committing itself to solving some of the world's most urgent health problems. Beyond pharmaceuticals, the company has expanded into the nutrition sector by launching its own range of in-house developed products for children. With its Easyfive-TT® vaccine, the company has supplied more than 190 million doses to over 75 countries, playing a key role in global immunization.;
CEO/MD
Dr. Rajesh Jain
Founded in
1984
NSE symbol
PANACEABIO

Shareholding pattern

Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Shareholder details

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
₹373.15
-0.45 (0.12%)
L
    H
    10,580.56--15.45
    ₹300.00
    -3.00 (0.99%)
    L
      H
      3,398.4819.782.08
      ₹51.20
      -2.65 (4.92%)
      L
        H
        243.67--6.08
        ₹2.78
        0.00 (--)
        L
          H
          21.06--2.51
          Livesquawk
          Panacea Biotec reports Q1 revenue of 2B rupees, up from 1.7B YOY. Year-over-year growth reflects improved financial performance.
          Livesquawk
          Panacea Biotec joins Denstar project to advance dengue vaccine licensure in Africa. The initiative aims to broaden global access to the dengue vaccine.
          2026
          13
          Aug
          Quarterly Result
          Release date
          30
          May
          Quarterly & Annual Result
          Release date
          29
          May
          Result
          Release date
          11
          Feb
          Quarterly Result
          Release date
          2025
          14
          Nov
          Quarterly Result
          Release date
          14
          Aug
          Quarterly Result
          Release date
          Events calendar
          View upcoming events in other stocks